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ABSTRACT
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with a high 
metastatic potential. The majority of MCC cases are caused by the Merkel cell 
polyomavirus (MCPyV), through expression of the virus-encoded tumour antigens. 
Whilst mechanisms attributing tumour antigen expression to transformation are 
being uncovered, little is known of the mechanisms by which MCPyV persists in the 
host. We previously identified the MCPyV small T antigen (tAg) as a novel inhibitor 
of nuclear factor kappa B (NF-κB) signalling and a modulator of the host anti-
viral response. Here we demonstrate that regulation of NF-κB activation involves 
a previously undocumented interaction between tAg and regulatory sub-unit 1 of 
protein phosphatase 4 (PP4R1). Formation of a complex with PP4R1 and PP4c is 
required to bridge MCPyV tAg to the NEMO adaptor protein, allowing deactivation of 
the NF-κB pathway. Mutations in MCPyV tAg that fail to interact with components of 
this complex, or siRNA depletion of PP4R1, prevents tAg-mediated inhibition of NF-κB 
and pro-inflammatory cytokine production. Comparison of tAg binding partners from 
other human polyomavirus demonstrates that interactions with NEMO and PP4R1 are 
unique to MCPyV. Collectively, these data identify PP4R1 as a novel target for virus 
subversion of the host anti-viral response.
INTRODUCTION
Merkel Cell Carcinoma (MCC) is a rare and highly 
malignant neuroendocrine carcinoma of the skin with a high 
level of metastasis and poor five-year survival rate [1, 2]. In 
2008, the DNA of a novel member of the Polyomaviridae, 
Merkel cell polyomavirus (MCPyV), was detected in MCC 
samples [3]. Epidemiological studies demonstrate that viral 
DNA is clonally integrated in approximately 80% of MCC 
investigated [3]. In keeping with other polyomaviruses, 
MCPyV expresses early proteins including the large (TAg) 
and small (tAg) tumour antigens, and a number of splice 
variants thereof [4]. These function as regulatory proteins and 
are essential for virus replication and pathogenesis. MCPyV 
isolated from MCC contains a truncated form of LT that 
retains the amino terminus but lacks the carboxyl-terminus 
helicase domain and is defective for virus replication [3]. 
MCPyV T-antigens are essential for MCC cell survival and 
proliferation, and depletion of either protein using siRNA 
leads to cell cycle arrest and apoptosis [4]. In agreement with 
these observations, mice genetically engineered to express 
MCPyV T antigens in the stratified epithelium display signs 
of neoplastic progression including unscheduled DNA 
synthesis, increased cellular proliferation and evidence of 
DNA damage. These data support the theory that MCPyV T 
antigens are oncogenic [5]. Unlike Simian Virus 40 (SV40), 
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MCPyV tAg expression is sufficient to transform rodent 
fibroblasts to contact- and anchorage-independent growth, 
and allows serum independent proliferation of human 
cells [6]. A number of host binding partners are required 
for MCPyV functions [1, 7]. For example, MCPyV tAg 
binding to the ubiquitin ligase complex SCFFbw7 prevents 
the ubiquitin-dependent degradation of TAg and a number 
of host cell oncoproteins [8]. Mutational studies identified 
a stretch of 5 amino acids (91-95) within tAg, termed the 
LT-stabilisation domain (LSD), to be essential for this 
function [8]. Expression of MCPyV tAg also results in the 
hyperphosphorylation of the translational regulator 4E-BP1, 
resulting in the deregulation of cap-dependent translation 
[6]. The cellular microtubule network is destabilized in 
cells expressing tAg, and this is associated with reduced 
phosphorylation of the microtubule regulatory protein 
Stathmin [9]. Targeting this pathway enhances MCC 
migration and invasion, which may explain the highly 
metastatic nature of MCPyV-associated MCC [7]. Expression 
of tAg also perturbs the host anti-viral immune response by 
inhibiting activation of the nuclear factor kappa B (NF-κB) 
transcription factor [10]. Down-regulation of this pathway 
likely contributes to the chronic nature of MCPyV infection. 
Similar to other polyomaviruses, tAg binds to members of 
the protein phosphatase family of enzymes, including PP2A 
Aα, PP2A Aβ and PP4c [10, 11]. Whilst the role of the PP2A 
Aα interaction is not clear, mutational studies implicate PP2A 
Aβ and PP4c in the control of NF-κB activation [10].
NF-κB is a family of transcription factors that play 
essential roles in the host response to infection [12]. The 
family consists of five structurally homologous members that 
form dimers sequestered in the cytoplasm of unstimulated 
cells, via an interaction with inhibitor of κB (IκB) proteins 
[13]. NF-κB is activated in response to a wide range of 
factors including pro-inflammatory cytokines (e.g. tumour 
necrosis factor alpha (TNFα)) or engagement of pattern 
recognition receptors (PRRs) by their ligands (e.g. dsRNA 
or hypomethylated DNA). Receptor activation initiates 
downstream signalling events that culminate in activation 
of the IκB kinase (IKK) complex [14]. This complex 
consists of two catalytic sub-units, IKKα and IKKβ, and 
a third, non-catalytic, adaptor protein termed IKKγ or NF-
κB essential modulator (NEMO). NEMO is a 419 amino 
acid protein containing two coiled-coil domains (CC1 and 
CC2), a ubiquitin-binding in ABIN and NEMO (UBAN) 
domain, a leucine zipper (LZ) and zinc finger domain 
[15]. IKKα/β are each bound constitutively to a NEMO 
dimer through residues 50-86 in NEMO. Recruitment of 
NEMO to hybrid linear/Lysine-(K)63-linked polyubiquitin 
chains brings the IKK complex into proximity of TAK1, 
which phosphorylates and activates the IKK complex [16]. 
Activated IKK phosphorylates IκBα, resulting in its rapid 
ubiquitin-dependent degradation, allowing the released 
NF-κB dimer to translocate to the nucleus and activate the 
transcription of genes associated with inflammation and the 
anti-viral response.
Our group identified a functional interaction between 
tAg and NEMO in cells and showed that this interaction 
was necessary for the inhibition of NF-κB dependent 
transcription in MCC cell lines [10]. Polyomaviruses 
mediate many of their effects through their manipulation 
of host protein phosphatases [11, 17]. Whilst MCPyV 
tAg targets PP2A Aα through direct protein-protein 
interactions, mutations in tAg that impair this interaction 
(e.g. R7A) do not prevent inhibition of NF-κB activation 
[10]. Instead, using a SILAC based quantitative proteomic 
approach; we identified a novel interaction with the 
catalytic sub-unit of the PP4 phosphatase. This interaction 
was essential for the reduction in IKK activity observed 
in MCPyV tAg expressing cells. Whilst tAg and NEMO 
may interact in a protein complex, the molecular basis 
by which tAg associates with NEMO is unclear. In this 
study, we show that NEMO is not a direct binding partner 
of tAg. Rather, we identify PP4 and its regulatory sub-
unit, PP4R1, as necessary for generating a tAg-NEMO 
complex. Using specific tAg mutants able to discriminate 
between distinct host phosphatase sub-units, and an siRNA 
depletion approach, we validated the importance of PP4R1 
for inhibition of NF-κB by MCPyV. Finally, screening 
with tAg from a number of polyomaviruses showed that 
binding to PP4R1 and NEMO was unique to MCPyV. 
Together, these data indicate that MCPyV utilizes unique 
interactions with cellular phosphatases to inhibit a critical 
antiviral pathway.
RESULTS
Mutations in the UBAN domain of NEMO 
prevent the interaction with MCPyV tAg in cells
We previously demonstrated that tAg interacts 
with NEMO in cells [10]. To investigate the mechanisms 
mediating this interaction, we firstly generated NEMO 
deletion mutants containing the region responsible 
for IKKα/β binding, the UBAN domain and the zinc 
finger (Figure 1A). All truncation mutants expressed to 
varying levels in MCC13 Merkel cell carcinoma cells 
(Figure 1B). Co-immunoprecipitation experiments 
showed that tAg only interacted with full-length NEMO 
(1-419) and truncations containing the UBAN domain 
(e.g. NEMO 246-419). NEMO truncations consisting of 
the amino terminal domain, necessary for binding the 
IKK complex, failed to interact with tAg (e.g. NEMO 
1-246). To confirm these results, two internal deletion 
mutants of NEMO were generated in which regions of the 
coiled-coil domain (NEMO Δ246-302) or leucine zipper 
(NEMO Δ302-365) were removed. Whilst these internal 
deletions expressed to wild-type levels, only the coiled-
coil domain deletion bound to tAg at similar levels to wild 
type NEMO, whereas the leucine zipper deletion mutant 
abrogated the interaction with tAg (Figure 1C). Several 
studies have identified mutations within this region of 
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NEMO in patients suffering from immunodeficiencies 
[18, 19]. A small number of characterized mutants were 
generated, known to disrupt specific functions of NEMO 
[18, 19]. Two mutations were generated in the UBAN 
domain, D311N and R319Q. Mutation of either residue 
has been shown to abrogate the binding of NEMO to 
ubiquitin and to prevent activation of NF-κB in response 
to a number of stimuli [20]. In addition, two mutants were 
generated outwith the UBAN domain to act as controls 
in the experiment. An A288G mutation in NEMO affects 
the second coiled-coil domain and destabilizes NEMO 
oligomers, resulting in impaired activation of NF-κB [21]. 
Finally, a C417R substitution modifies the structure of 
the carboxyl-terminal zinc finger and impairs activation 
of NF-κB in response to CD40 ligation [22]. After 
confirming that all four mutants expressed to comparable 
Figure 1: The NEMO UBAN domain is necessary for tAg binding in cells. (A) Schematic representation of the FLAG-tagged 
NEMO truncations and internal deletions. (B) MCC13 cells were transfected with plasmids encoding GFP fusion proteins and a panel of 
FLAG-tagged NEMO truncations. GFP-TRAP co-immunoprecipitations were performed on the transfected lysates, and both input lysates 
and precipitations were probed with antibodies against GFP and FLAG. Lysates probed with an antibody detecting GAPDH served as a 
loading control. (C) GFP-TRAP co-immunoprecipitations were performed with a GFP control or GFP MCPyV tAg and two FLAG-tagged 
internal deletions of NEMO. Precipitations and lysates were analyzed as above. (D) MCC13 cells were transfected with plasmids encoding 
GFP fusion proteins and GST-tagged NEMO point mutants. GFP-TRAP co-immunoprecipitations were performed on the transfected 
lysates, and both lysate and precipitation were probed with antibodies against GFP and GST. GAPDH served as a loading control. Western 
blots shown are representative from at least three independent experimental repeats.
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levels as wild type NEMO, we next compared their ability 
to interact with tAg using co-immunoprecipitation assays. 
Interestingly, we found that NEMO containing the R319R 
substitution within the UBAN domain could bind tAg, 
but the D311N substitution failed to interact with tAg 
(Figure 1D). As expected, based on results obtained using 
the NEMO internal deletions, substitution of A288G or 
C417R had negligible impact on binding to tAg.
NEMO does not interact directly with MCPyV 
tAg in vitro
We previously demonstrated that tAg interacts with 
NEMO and the catalytic sub-unit of the PP4 phosphatase 
(PP4c) in cells [9, 10]. To understand the mechanism of 
these interactions, we wished to determine whether tAg 
interacted directly with NEMO or PP4c. For this, NEMO 
and PP4c were generated by in vitro coupled transcription/
translation (ITT), and used in GST pull-down experiments 
with bacterial expressed GST-tAg [23]. Analysis showed 
that, in contrast to PP4c, GST-tAg did not bind directly 
to NEMO (Figure 2A). It was possible that tAg might 
recruit NEMO in a PP4c-dependent manner; therefore, 
we next determined whether co-incubation with NEMO 
and PP4c would recapitulate the tAg-NEMO interaction 
we had observed in cells. GST pull-downs were performed 
in mixed reactions containing ITT produced NEMO and 
PP4c. Even with the presence of PP4c, GST-tAg was not 
Figure 2: MCPyV tAg interacts with PP4c but not NEMO in vitro. (A) Equal amounts of bacterially expressed GST and GST-
tAg were bound to glutathione-agarose beads and incubated with ITT produced FLAG-tagged PP4c and NEMO alone or in combination. 
Following washes, bound proteins were separated by SDS PAGE and probed with antibodies against GST and FLAG. A sample of the 
ITT input was analyzed to confirm appropriate expression of the FLAG-tagged proteins. (B) Equal amounts of bacterially expressed 
GST and GST-NEMO were bound to glutathione-agarose beads and incubated with ITT produced FLAG-tagged PP4c and tAg alone or 
in combination. Following washes, bound proteins were separated by SDS PAGE and probed with antibodies against GST and FLAG. A 
sample of the ITT input was analyzed to confirm appropriate expression of the FLAG-tagged proteins. Western blots are representative of 
at least three independent repeats.
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able to bind to NEMO in vitro. Reciprocal experiments 
using a bacterial expressed GST-NEMO as bait for 
interaction with ITT expressed PP4c or tAg were in 
agreement, showing only an interaction between NEMO 
and PP4c (Figure 2B). These data determine that tAg binds 
to PP4c in vitro but that the interaction between tAg and 
NEMO must be mediated through an additional interaction 
beyond PP4c.
PP4R1 is a novel tAg binding partner
The failure of PP4c to recapitulate an interaction 
between tAg and NEMO in vitro suggested that a further 
host protein partner was necessary to allow tAg to complex 
with NEMO. PP4c has been shown to associate with 
the non-catalytic protein phosphatase 4 regulatory sub-
unit 1 (PP4R1) in the cytoplasm of cells [24]. Given the 
crucial role of these scaffolding sub-units in phosphatase 
function, we set out to determine whether PP4R1 might be 
required for tAg-mediated inhibition of NF-κB. Initially, 
we evaluated whether endogenous PP4R1 was able to 
interact with PP4c and NEMO in MCC13 cells. FLAG-
tagged versions of PP4c and NEMO were precipitated 
from MCC13 cells and western blot analysis showed that 
endogenous PP4R1 interacted with both proteins (Figure 
3A and 3B). Next, we explored whether PP4R1 interacts 
with tAg. Firstly, MCC13 cells were transfected with GFP 
or GFP-tAg and precipitations performed using GFP-
TRAP beads. Results show that endogenous PP4R1 bound 
to GFP-tAg but not GFP alone (Figure 4A). To ensure that 
the interaction observed was not a result of tAg over-
expression, lysates were generated from MKL1 cells, a 
MCPyV positive MCC tumour cell line. Lysates were next 
precipitated with an anti-PP4R1 antibody or a pre-immune 
IgG control. Tumour expressed tAg was successfully 
precipitated with endogenous PP4R1 but not with the pre-
immune IgG control (Figure 4B). These data demonstrate 
that tAg interacts with PP4R1 in a MCPyV positive MCC 
cell line. Together, these data provide the first evidence of 
a viral protein associating with PP4R1.
PP4R1 is required for the interaction between 
tAg and NEMO
Having established that tAg, PP4c and NEMO 
associate with PP4R1 in cells, we sought to determine 
whether PP4R1 functions as an adaptor in the tAg-
NEMO complex. To this end, we repeated in vitro binding 
assays using bacterial expressed GST-tAg (Figure 4C) 
or GST-NEMO (Figure 4D) and ITT produced binding 
partners. As before, PP4c but not NEMO bound directly 
to recombinant GST-tAg. PP4R1 was also able to 
bind directly to GST-tAg and GST-NEMO in vitro but, 
similar to PP4c, could not recapitulate the tAg-NEMO 
interaction. Only when PP4R1-PP4c and NEMO were 
combined was GST-tAg able to bind to NEMO in the 
in vitro assay (Figure 4C). If the interactions observed 
between tAg and NEMO observed in cells are facilitated 
by PP4c-PP4R1, then mutations in the NEMO UBAN 
domain that impair the interaction with tAg (Figure 1D) 
should not interact with PP4c-PP4R1. To investigate this 
possibility, co-immunoprecipitations were performed from 
cells expressing GST-NEMO or GST-NEMO D311N and 
endogenous PP4c-PP4R1. In agreement with our previous 
result, introduction of the single point mutation into the 
UBAN domain of NEMO abrogated the interaction with 
GFP-tAg (Figure 4E). This mutation also significantly 
decreased binding to endogenous PP4c and PP4R1, further 
suggesting that these phosphatase sub-units are recruited 
to the IKK complex via interactions with NEMO.
Mapping of tAg residues necessary for 
interacting with NEMO and phosphatase sub-
units
Studies using deletion analysis indicated that tAg 
bound to NEMO and the phosphatases PP2A Aβ and 
PP4c through a 16 amino stretch (residues 95 -111) [10]. 
Consistent with this, an internal deletion mutant of tAg 
lacking these residues was incapable of blocking NF-κB 
mediated transcription [10]. To determine which residues 
within this region were required for interaction with 
NEMO and the phosphatase sub-units, we undertook a 
mutagenesis screen in which residues were mutated to 
alanine, or existing alanines changed to arginine, in sets 
of 4. We then investigated the effect of these mutations 
on the ability of tAg to bind to NEMO, PP4c, PP4R1 
and PP2A Aβ. Most mutations did not affect the binding; 
however, mutation of N100-F103 prevented binding to 
all proteins under study (data not shown). To investigate 
further, point mutations were generated in this region 
and tested for interactions with the panel of binding 
partners. Mutation of N100 had no significant impact on 
binding to NEMO or PP4c, although some reduction was 
observed for PP4R1, which likely reflects the reduced 
levels of the GFP-N100A protein. Mutation of A101, 
R102 or F103 disrupted binding of tAg to both NEMO 
and PP4R1, whilst binding to PP4c was diminished 
upon mutation of A101 and abrogated in the R102-F103 
mutants (Figure 5A-5C). In contrast, the interaction with 
PP2A Aβ was only lost in the F103A mutant (Figure 
5D). Importantly, all of the point mutants retained the 
ability to stimulate expression from the MCPyV early 
promoter, up-regulating the promoter reporter plasmid by 
approximately 5-fold, similar to wild-type tAg, compared 
with a GFP control (Figure 5E). These results indicate 
that the point mutations retain other tAg functions. 
We next determined the effect of the point mutants 
on the ability of tAg to down-regulate NF-κB-driven 
transcription using a luciferase reporter system. As seen 
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previously, tAg expression strongly inhibited NF-κB-
driven luciferase expression in response to treatment 
with TNFα (Figure 5F). A similar level of inhibition was 
observed for the N100A mutant, which retained binding 
to NEMO and the phosphatases. In contrast, tAg with 
mutations in A101-R102 showed a reduced ability to 
inhibit NF-κB transactivation, which was fully restored 
to control levels in the F103 mutant (Figure 5F). To 
verify the results using a more physiologically relevant 
indicator, we analyzed the media from mock and treated 
samples for levels of the pro-inflammatory cytokine 
IL-8 and the chemokine CCL20 (Figure 5G and 5H). As 
NF-κB-dependent gene products, their expression was 
increased upon stimulation with TNFα and their relative 
levels reflected the data obtained using the luciferase 
reporter plasmid system.
PP4R1 is crucial for tAg-mediated inhibition of 
NF-κB activation
To substantiate a role for PP4R1 in perturbation 
of NF-κB activation by tAg, NEMO-tAg complex 
Figure 3: PP4R1 interacts with PP4c and NEMO in MCC13 cells. MCC13 cells were transfected with empty plasmid or FLAG-
tagged (A) PP4c or (B) NEMO. Immunoprecipitations were performed using FLAG-agarose beads and analyzed by western blot with 
antibodies against FLAG or endogenous PP4R1. Total cell lysates served as a positive control for expression. Western blots shown are 
representative of at least three independent experiments.
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formation was measured in addition to NF-κB-dependent 
production of pro-inflammatory cytokines in cells 
depleted of PP4R1. MCC13 cells were transfected with 
scrambled or PP4R1-specific siRNAs, and after 24 hours 
further transfected with either GFP or GFP-tAg and 
incubated for a further 24 hours prior to cell lysis and 
analysis of tAg interacting partners. Immunoblotting 
with an antibody detecting endogenous PP4R1 confirmed 
efficient knockdown (Figure 6A). PP4R1 depletion had no 
overall impact on levels of PP4c or NEMO expression. 
GFP immunoprecipitations were performed from siRNA 
transfected cell lysates, and the precipitates probed with 
Figure 4: PP4R1 is a novel tAg binding partner required for NEMO binding. (A) GFP-TRAP co-immunoprecipitations 
were performed on lysates from MCC13 cells transfected with plasmids expressing GFP or GFP-tAg and analyzed by western blot with 
antibodies against GFP and endogenous PP4R1. Total cell lysates served as a positive control for protein expression and GAPDH as a 
loading control. (B) MKL1 cell lysates were precipitated with an anti-PP4R1 antibody or a pre-immune IgG control and analyzed by 
western blot. Samples were probed with antibodies against PP4R1, tAg (2T2) and GAPDH served as a loading control. (C) Equal amounts 
of bacterially expressed GST and GST-tAg were bound to glutathione-agarose beads and incubated with ITT produced HA-PP4R1 and 
FLAG-PP4c/NEMO alone or in combination. Following washes, bound proteins were separated by SDS PAGE and probed with antibodies 
against GST, HA and FLAG. A sample of the ITT input was analyzed to confirm appropriate expression of the epitope-tagged proteins. (D) 
Equal amounts of bacterially expressed GST and GST-NEMO were bound to glutathione-agarose beads and incubated with ITT produced 
HA-PP4R1 and FLAG-PP4c/tAg alone or in combination. Following washes, bound proteins were separated by SDS PAGE and probed 
with antibodies against GST, HA and FLAG. A sample of the ITT input was analyzed to confirm appropriate expression of the epitope-
tagged proteins. (E) MCC13 cells were transfected with plasmids expressing GST, GST-NEMO or GST-NEMO D311N in combination 
with GFP-tAg. Cell lysates were incubated with glutathione-agarose beads and precipitates probed with antibodies against GST, GFP, PP4c 
and PP4R1. Total cell lysates served as an expression control and GADPH as a loading control. Western blots shown are representative of 
at least three independent experimental repeats.
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Figure 5: Mapping the residues in MCPyV tAg necessary for inhibition of NF-κB activation. GFP-TRAP co-
immunoprecipitations were performed using MCC13 cells co-transfected with plasmids expressing GFP, GFP-tAg or a panel of tAg point 
mutants in the presence of (A) a Myc-NEMO expression plasmid, (B) FLAG-PP4c expression plasmid, (C) HA-PP4R1 expression plasmid 
or (D) EE-tagged PP2A Aβ expression plasmid. Transfected cell lysates were incubated with GFP-TRAP affinity beads and bound protein 
was western blotted with antibodies detecting GFP and the appropriate epitope tag. Total cell lysates served as a positive control for 
protein expression and GAPDH as a loading control. (E) MCC13 cells were transfected with plasmids encoding the GFP-fusion proteins 
described and a luciferase reporter plasmid encoding the MCPyV early promoter [10]. Cell lysates were harvested after 24 hours and used 
in luciferase assays. (F) MCC13 cells were transfected with plasmids expressing GFP-fusion proteins and a reporter plasmid driving firefly 
luciferase under the control of NF-κB elements from the Concanavalin A promoter. Cells were treated with 10 ng/mL TNFα for 8 hours 
and samples analyzed for luciferase activity. To normalize for differences in transfection efficiency cells were co-transfected with a renilla 
luciferase reporter plasmid, and values were normalized relative to renilla expression. (G) IL-8 and (H) CCL20 protein levels in TNFα 
stimulated cells. Cells were stimulated as in (F), and media collected at 24 hours post stimulation for analysis by ELISA for each cytokine. 
Data are presented as picograms of cytokine. Error bars are +/−SD. Significance was analyzed by student’s t-test and is indicated by an 
asterix *p<0.05, **p<0.01, ***p<0.001. Data shown are representative of at least three independent experimental repeats.
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antibodies against GFP, PP4R1, PP4c and NEMO. As 
expected, GFP-tAg successfully precipitated endogenous 
NEMO, PP4R1 and PP4c from scramble siRNA treated 
cells (Figure 6A). In contrast, absence of PP4R1 abrogated 
the interaction between GFP-tAg and NEMO, whilst 
leading to a reduction in the level of PP4c bound (Figure 
6A), which confirms that PP4R1 is essential to direct tAg 
to NEMO in cells.
Our data indicates that PP4R1 directs tAg-PP4c to 
NEMO in order to inhibit the IKK complex. To further 
address this point, NF-κB-dependent luciferase reporter 
assays were performed in tAg expressing cells depleted 
of PP4R1. As expected, NF-κB activation was increased 
in PP4R1 depleted cells compared to the scramble control 
and NF-κB activation was further augmented when cells 
were treated with TNFα (Figure 6B). Importantly, the 
Figure 6: PP4R1 is necessary for MCPyV tAg-mediated inhibition of NF-κB. (A) Plasmids expressing GFP or GFP-tAg 
were transfected into MCC13 cells pre-transfected with scrambled or PP4R1-specific siRNA and GFP-TRAP co-immunoprecipitations 
performed. Precipitated protein complexes were separated by SDS PAGE and western blot performed with antibodies against GFP and 
endogenous PP4R1, PP4c and NEMO. Total lysates served as positive controls for protein expression, and confirmed PP4R1 depletion, 
whilst GAPDH acted as a loading control. (B) MCC13 cells containing scrambled control or PP4R1-specific siRNA were transfected 
with plasmids expressing GFP or GFP-tAg and a reporter plasmid driving firefly luciferase under the control of NF-κB elements from the 
Concanavalin A promoter. Cells were treated with 10 ng/mL TNFα for 8 hours and samples analyzed for luciferase activity. To normalize 
for differences in transfection efficiency cells were co-transfected with a renilla luciferase reporter plasmid, and values were normalized 
relative to renilla expression. (C) IL-8 and (D) CCL20 protein levels in TNFα stimulated cells. Cells were stimulated as in (B), and media 
collected at 24 hours post stimulation for analysis by ELISA for each cytokine. Data are presented as picograms of cytokine. Error bars 
are +/−SD. Significance was analyzed by student’s t-test and is indicated by an asterix *p<0.05, **p<0.01, ***p<0.001. Data shown are 
representative of at least three independent experimental repeats.
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impairment of NF-κB activation by tAg was lost both 
in control and TNFα treated cells. Silencing of PP4R1 
significantly increased IL-8 and CCL20 protein production 
in MCC13 cells upon treatment with TNFα (Figure 6C-
6D). Although basal levels of cytokine were increased 
marginally in the absence of PP4R1, the increase was not 
to the extent observed upon stimulation. In agreement 
with the luciferase reporter assay studies, tAg-mediated 
suppression of pro-inflammatory cytokine protein levels 
was significantly reduced in the absence of PP4R1. 
Collectively, these results show that PP4R1 is essential for 
the suppression of NF-κB signalling by tAg in MCC13 
cells.
Interactions with PP4R1 and NEMO are 
restricted to MCPyV tAg
Given its essential nature, we wished to determine 
whether the tAg of other human polyomaviruses interact 
with NEMO and protein phosphatases. We investigated 
three additional polyomaviruses, namely BK and JC, 
which are human pathogens and SV40. MCC13 cells were 
co-transfected with GFP-tAg and epitope tagged versions 
of NEMO and a panel of phosphatase sub-units (Figure 7). 
Despite the variations in tAg expression, all tAg tested 
precipitated PP2A Aα, whereas only MCPyV interacted 
with PP2A Aβ, as previously published [10, 25]. Our 
results also confirmed the recently published interaction 
between SV40 tAg and PP4c [11]. Interestingly, the tAg 
of SV40, JC and BK did not bind to PP4R1 or NEMO. 
Only MCPyV was able to precipitate PP4R1 and NEMO 
from cells. These data further indicate that an interaction 
between tAg and PP4c alone is not sufficient to mediate an 
interaction with NEMO in cells.
DISCUSSION
Detection of viral infection by components of the 
innate immune system activates signalling cascades that 
lead to the production of interferons and inflammatory 
cytokines, in order to eliminate the infection [12]. Amongst 
these, NF-κB is crucial for activating inflammatory 
immune responses [13, 26]. Binding of the adaptor protein 
NEMO to upstream proteins is a critical signalling node 
that links stimulated receptors to activation of the IKK 
complex. Subsequent phosphorylation of inhibitory IκB 
proteins by the IKK complex is a key step in the activation 
of NF-κB family members and critically represents a focal 
point of classical NF-κB signalling. Given its importance, 
many viruses have evolved to target components of the 
IKK complex to suppress NF-κB activation [27–30]. 
We previously described that MCPyV tAg was able to 
Figure 7: Binding to NEMO and PP4R1 is not conserved amongst PyV tAg. (A) Total lysates from MCC13 cells transfected 
with plasmids expressing GFP and GFP-tAg from MCPyV, SV40, BKPyV and JCPyV in the presence of FLAG-PP4c, HA-PP4R1, EE-
PP2A Aα, EE-PP2A Aβ or Myc-NEMO expression plasmids. GAPDH served as a loading control. (B) GFP-TRAP co-immunoprecipitations 
performed from cell lysates and western blots probed with antibodies against GFP and the appropriate epitope tag. Western blots shown are 
representative of five independent experimental repeats.
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prevent IKK phosphorylation by a mechanism requiring 
interactions with the IKK adaptor protein NEMO and 
the catalytic sub-unit of PP4 [10]. Dephosphorylation is 
an essential regulatory element in the NF-κB pathway; 
however, the identity and control of phosphatases that 
regulate IKK are not well defined. Deletion analysis 
showed that the amino terminus of NEMO, required 
for interactions with IKKα/β, was dispensable for tAg 
binding. Rather, we demonstrated that the NEMO UBAN 
domain was necessary for the observed interaction. The 
UBAN is a coiled-coil rich domain shown to preferentially 
bind to linear ubiquitin chains, and also form lower 
affinity complexes with longer K-63 linked polyubiquitin 
chains [15, 20, 31, 32]. UBAN is essential for recruiting 
NEMO to upstream signalling complexes and specific 
point mutations in this domain prevent TNFα and IL-1-
mediated NF-κB activation [33]. Co-immunoprecipitations 
with a panel of NEMO proteins containing point mutants 
associated with immunodeficiency disorders reinforced 
the importance of the UBAN domain for the interaction 
with tAg. Using a point mutant that affects a conserved 
aspartic acid (D311N) within this domain, identified 
in X-linked anyhydrotic ectodermal dysplasia with 
immunodeficiency, prevented the interaction with tAg in 
cells. The mutation of this residue prevents NEMO from 
binding to linear and K-63 linked ubiquitin chains and 
abrogates recruitment to upstream signalling complexes 
[34]. Interestingly, the R319Q mutation, which also 
resides within the UBAN domain, did not impact on 
the interaction with tAg. This mutant was shown to still 
partially interact with ubiquitin chains and to have a less 
pronounced phenotype than the D311N mutant [35]. These 
data indicate that the interaction between tAg and NEMO 
requires an intact UBAN domain, which may be necessary 
to facilitate recognition of specific protein complexes or 
ubiquitylated interaction partners. We further explored 
tAg-NEMO binding requirements using a combination 
of recombinant GST-tAg/NEMO and in vitro transcribed/
translated binding partners. Surprisingly, in contrast with 
co-immunoprecipitation data, no interaction was observed 
between tAg and NEMO, suggesting that NEMO is 
not a direct binding partner of tAg. This might explain 
the failure to detect NEMO in the initial tAg SILAC 
proteomic screen [10]. In contrast, PP4c was readily 
precipitated by both NEMO and tAg. These findings 
suggest that an essential linker protein may be required to 
bridge NEMO to tAg. PP4c was an obvious candidate for 
this role, given its co-localization with NEMO and tAg in 
discrete cytoplasmic puncta [10], however, introduction 
of PP4c into the binding assays failed to recapitulate a 
tAg-NEMO interaction in vitro. Given that MCPyV tAg 
interacts with a range of phosphatase sub-units [10, 11], 
it was possible that an alternative phosphatase might 
function as the bridge to NEMO. A number of lines of 
evidence suggested that this was unlikely. Firstly, whilst 
PP2A has been shown to dephosphorylate proteins within 
the NF-κB pathway, a tAg mutant (R7A) unable to interact 
with PP2A Aα was still capable of inhibiting NF-κB 
activation [10]. Secondly, a growing body of evidence 
identifies PP4 as a key negative regulator of NF-κB [36–
38]. A range of regulatory sub-units controls the catalytic 
activity of PP4. These constrain the broad acting catalytic 
sub-unit activity by restricting its subcellular locations and 
directing it towards specific substrates [39]. Recently, the 
regulatory sub-unit PP4R1 has been shown to negatively 
regulate NF-κB signalling in T cells by directing PP4c to 
dephosphorylate the IKK complex [37]. We confirmed that 
endogenous PP4R1 interacted with NEMO and PP4c in 
MCC13 cells, suggesting that similar inhibitory protein 
complexes might form in these cells. Importantly we also 
confirmed that PP4R1 was a novel binding partner of tAg 
in MCPyV positive cells. To our knowledge, this is the 
first evidence for a virus protein targeting this phosphatase 
sub-unit. PP4R1 also bound to both NEMO and tAg in 
vitro but was not sufficient to recapitulate the NEMO-tAg 
interaction. Only the combined presence of PP4R1-PP4c 
recapitulated the NEMO-tAg interaction in vitro. Together, 
these binding studies suggest that whilst tAg is not able to 
bind with NEMO in vitro, it interacts with a PP4R1-PP4c 
phosphatase complex, which mediates the interaction 
with NEMO to dephosphorylate the IKK complex. In 
support of this idea, the NEMO UBAN mutant that does 
not bind with tAg in cells was also less able to interact 
with PP4R1-PP4c in co-immunoprecipitation assays. 
Whether the NEMO UBAN interacts with an ubiquitylated 
form of PP4R1-PP4c or if it has an additional function 
as a protein interaction domain is not currently known. 
Importantly, PP4R1 recruits tAg to NEMO, and absence of 
PP4R1 prevented co-precipitation of NEMO with tAg in 
cells. Although PP4c was still detected in tAg precipitates 
in PP4R1 depleted cells, levels were reduced compared 
to a scrambled control. This suggests that tAg is able to 
interact with PP4c in the absence of PP4R1; however, 
presence of the targeting sub-unit enhances the interaction 
in cells. Depletion of PP4R1 increased levels of basal and 
stimulus-dependent NF-κB activity, and increased the 
production of the pro-inflammatory cytokines IL-8 and 
CCL20, whilst also preventing tAg-mediated inhibition 
of the pathway. These data confirm reports that PP4R1 
is necessary for the shutdown of NF-κB activity, and 
importantly show that its loss prevents tAg subversion of 
this pathway.
Whilst there is evidence for binding to a range of 
phosphatase sub-units by MCPyV tAg, the molecular 
mechanisms and physiological outcome of many of 
these interactions are unclear. In this regard, the use of 
point mutations to abrogate the interaction with specific 
phosphatases has been illuminating. For example, the 
R7A mutation prevents interaction with PP2A Aα, and this 
mutant has allowed the exclusion of a role for PP2A Aα in 
the regulation of 4EBP1 hyperphosphorylation and in tAg 
mediated transformation [11]. In contrast, generation of 
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mutants able to discriminate between PP2A Aβ and PP4c 
has been lacking. Alanine scanning allowed us to develop 
the first tAg mutants able to selectively prevent binding to 
PP4c whilst retaining an interaction with PP2A Aβ. Using 
these mutants we were able to verify that loss of PP4c 
binding correlated with the loss of NF-κB transcriptional 
inhibition, as measured by luciferase reporter assay 
and ELISA detection of pro-inflammatory cytokine 
production. In the future, these mutants will provide a 
valuable resource to investigate which phosphatase sub-
units are necessary for the range of functions ascribed to 
tAg, including modulation of the host factor Stathmin [9] 
or 4EBP1 hyperphosphorylation [6]. Interestingly, the 
PP4R1-NEMO interaction was not conserved with tAg 
of other human polyomaviruses, indicating that down-
regulation of NF-κB might be a feature only found in 
this virus. In support of this notion, the NARF sequence 
residing in residues 100-103 is not found in other family 
members, including the closely related Chimpanzee 
and Gorilla PyV. The unique wide range of phosphatase 
binding partners observed for MCPyV offers an exciting 
model whereby distinct pools of tAg exist in the cell, each 
bound by a sub-set of host factors and able to perform 
specific tasks during the infectious life cycle and in disease 
progression. Future work should focus on delineating 
these processes in greater detail.
Collectively, our data provide further evidence that 
tAg is a suppressor of NF-κB activation, which likely 
impairs the local innate immune response to MCPyV 
infection. We have identified an unexplored role for the 
PP4R1 phosphatase sub-unit in the inhibition of this 
pathway.
MATERIALS AND METHODS
Plasmids, siRNAs and antibodies
Expression plasmids for enhanced green fluorescent 
protein (GFP)-MCPyV tAg, glutathione S-transferase 
(GST)-NEMO and Myc-NEMO have been described 
previously [10]. EE-PP2A A, FLAG-PP4c and HA-PP4R1 
were kindly provided by Stefan Stack, Marilyn Goudreault 
and Arnold Rüdiger, respectively. pGFP-MCPyV tAg 
N100A, A101R, R102A and F103A, were produced using 
the QuikChange site directed mutagenesis kit (Stratagene), 
as directed by the manufacturer’s instructions. tAg were 
PCR amplified from genomic clones of SV40, BKPyV 
and JCPyV kindly provided by Eric Blair and Michael 
Imperiale. DNA inserts were cloned between the Eco RI 
and Bam HI sites of pGFP-C1. Truncation and internal 
deletion mutants of NEMO were generated by PCR and 
cloned between Bam HI and Not I restriction sites in 
pCMV5-FLAG. Point mutations in the UBAN domain 
of NEMO (A288G, D311N, R319Q and C417R) were 
generated with QuikChange using pEBG2T-NEMO as 
template. Bacterial expression of a GST-NEMO fusion 
protein was achieved by cloning NEMO into pGEX6P1 
as a Bam HI and Not I fragment. The MCPyV early 
promoter region was PCR amplified from MCC genomic 
DNA using primers incorporating KpnI and SmaI 
restriction sites, allowing the promoter to be inserted 5′ 
of the luciferase gene in pGL3-Basic, to generate pGL3-
Early [10]. Primer sequences are available on request. All 
inserts were sequence verified (GATC). PP4R1-specific 
small interfering RNAs (siRNAs) were purchased from 
Qiagen. Antibodies against PP4c, PP4R1, GAPDH (Santa 
Cruz), GFP, NEMO, Glu-Glu (EE) (Abcam), FLAG, GST 
and Myc (Sigma-Aldrich) were purchased from their 
respective suppliers. The 2T2 hybridoma, which detects 
MCPyV tAg was kindly provided by Chris Buck.
Cells
MCC13 (MCC positive, MCPyV negative) and 
MKL1 (MCC positive, MCPyV positive) cells were 
purchased from the ECACC and confirmed to be negative 
for Mycoplasma infection. Cells were cultured in RPMI 
1640 medium supplemented with 10% FBS and 1% 
penicillin-streptomycin in 5% CO
2
 at 37°C. MCC13 cells 
were transfected using Lipofectamine 2000 (Invitrogen) 
as described [10].
Western blotting
Cells were lysed in Leeds Lysis Buffer (LLB) 
[40] supplemented with protease inhibitor cocktail 
(Roche). Proteins were separated by SDS PAGE before 
transfer onto nitrocellulose membrane (HyBond, 
Amersham BioSciences) using a TransBlot Turbo 
(BioRad). Membranes were probed with appropriate 
primary antibody and horseradish conjugated secondary 
antibodies. Proteins were detected using ECL (Amersham 
BioSciences). Western blot analysis was carried out as 
previously described [10].
Immunoprecipitations
Assays were performed as previously described 
[41]. For epitope tag-based co-immunoprecipitations, 
MCC13 cells were transfected with the appropriate 
plasmids. Cell lysates were harvested and then incubated 
with GFP-TRAP M beads (Chromotek) or anti-FLAG M1 
affinity gel (Sigma-Aldrich) for 2-4 hours at 4°C or 1 hour 
at room temperature with vigorous shaking. Beads were 
washed in lysis buffer and then analyzed by immunoblot. 
For immunoprecipitation of endogenous proteins, MKL1 
cell lysates were precipitated with an anti-PP4R1 antibody 
or a pre-immune IgG control overnight at 4°C. Packed 
protein G beads (20 μl) were added to the lysates and 
antibody mix, and incubated for a further 1 hour at 4°C. 
Precipitates were washed extensively in lysis buffer and 
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boiled in Laemmli loading buffer prior to SDS PAGE and 
western blot analysis.
Luciferase reporter assays
MCC13 cells were transfected with 25 ng of 
reporter plasmid expressing firefly luciferase under the 
transcriptional control of the NF-κB elements from 
the concanavalin A promoter [42]. Where appropriate, 
cells were co-transfected with 1 μg of GFP or GFP-
tAg expression plasmids. To normalize for transfection 
efficiency, 5 ng of pRLTK, which drives renilla luciferase 
expression from a constitutive TK promoter, was added 
to each transfection. At 24 h post transfection, cells were 
serum starved for 6 h and then treated with 10 ng/mL 
TNFα for a further 8 h. Samples were lysed in Passive 
Lysis Buffer (PLB) (Promega), and levels of luciferase 
detected using a dual luciferase reporter assay (Promega), 
as previously described [43]. For analysis of MCPyV early 
promoter activation, 200 ng of MCPyV promoter reporter 
plasmid was co-transfected with 1 μg of GFP or GFP-
tAg expression plasmid and 5 ng pRLTK. Cells lysates 
were harvested after 24 hours and levels of luciferase 
determined as described above. Experiments were 
performed in triplicate and from at least three independent 
biological repeats.
Determination of secreted IL-8 and CCL20 
levels by ELISA
MCC13 cells expressing proteins of interest or 
treated with siRNA targeting PP4R1 were treated with 10 
ng/ml TNF-α, and supernatants were collected 24 h post-
treatment. Levels of secreted interleukin-8 (IL-8) and 
CCL20 were detected by enzyme-linked immunosorbent 
assay (ELISA) using the manufacturer's protocol (R&D 
Systems).
Expression and purification of recombinant 
proteins
Recombinant GST, GST-tAg and GST-NEMO 
were expressed and purified using protocols previously 
described [23].
In vitro pull-down assays
GST pull-down assays were performed as described 
previously [23, 44]. Briefly, GST fusion proteins were 
bound to glutathione-agarose beads at 4°C for 1 hour. 
Equal quantities of in vitro transcription/translation 
reactions (Promega TnT) expressing a protein of choice 
were incubated with beads in lysis buffer. After 3 hours 
of incubation the beads were washed extensively in lysis 
buffer, prior to analysis by SDS PAGE and Western 
blotting. GST alone served as a negative control.
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